3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Myelodysplastic Syndromes
13
Precursor Cell Lymphoblastic Leukemia-Lymphoma
9
Leukemia, Myeloid, Acute
9
Leukemia
8
Hematologic Neoplasms
7
Lymphoma, Non-Hodgkin
6
Lymphoma
6
Multiple Myeloma
4
Primary Immunodeficiency Diseases
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Hodgkin Disease
3
Cytopenia
3
Anemia, Aplastic
3
Thalassemia
2
Osteopetrosis
2
Neoplasm, Residual
2
Neoplasm Metastasis
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Immunoproliferative Disorders
2
Immune System Diseases
2
Hemoglobinopathies
2
Fanconi Anemia
2
Cytokine Release Syndrome
2
Breast Neoplasms
2
Anemia, Sickle Cell
2
Anemia, Diamond-Blackfan
2
Anemia
2
Uveal Melanoma
1
Triple Negative Breast Neoplasms
1
Thymoma
1
Interventions
Cyclophosphamide
2
toripalimab
1
pembrolizumab
1
fludarabine
1
apatinib
1
TP protocol
1
Surgical Procedures, Operative
1
Radiation
1
Heavy Ion Radiotherapy
1
Drug Therapy
1
Doxorubicin
1
Cisplatin
1
Carboplatin
1
AP 1903 reagent
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Thymic epithelial tumor
×
AP 1903 reagent
×
Clear all
NCT07598955
2026-05-20
SELECT-NK-THYM
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled